Xeris Biopharma Holdings (XERS) Other Working Capital Changes (2020 - 2026)

Xeris Biopharma Holdings has reported Other Working Capital Changes for 7 years, with the latest figure at -$145000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Working Capital Changes rose 90.54% year-over-year to -$145000.0; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (up 257.55% YoY), and the FY2025 full-year result was $2.1 million, up 2426.51% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$145000.0, up from -$1.3 million in the prior quarter.
• The five-year high for Other Working Capital Changes was $4.1 million in Q3 2025, with the low at -$2.1 million in Q2 2023.
• Historically, Other Working Capital Changes has averaged -$129375.0 across 5 years, with a median of -$101500.0 in 2022.
• The largest YoY upside for Other Working Capital Changes was 2012.07% in 2023 against a maximum downside of 3437.93% in 2023.
• Xeris Biopharma Holdings' Other Working Capital Changes stood at -$899000.0 in 2022, then slumped by 126.47% to -$2.0 million in 2023, then soared by 37.18% to -$1.3 million in 2024, then rose by 2.03% to -$1.3 million in 2025, then surged by 88.43% to -$145000.0 in 2026.
• The last three Other Working Capital Changes figures came in at -$145000.0 (Q1 2026), -$1.3 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.